An open-label pilot trial of ibandronate for complex regional pain syndrome

Clinical Journal of Pain

Volumn 24, Issue 8, 2008, Pages 685-689

  Breuer, Brenda ^a   Pappagallo, Marco ^b   Ongseng, Fukiat ^a   Chen, Chieh I ^a   Goldfarb, Richard ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Complex regional pain syndrome; CRPS; Ibandronate; Pilot trial; Reflex sympathetic dystrophy; RSD

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO; BONE DENSITY CONSERVATION AGENT;

ALLODYNIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERALGESIA; MALE; METHODOLOGY; NEUROPATHIC PAIN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT RESPONSE; ADULT; CHI SQUARE DISTRIBUTION; COMPLEX REGIONAL PAIN SYNDROME TYPE I; PAIN ASSESSMENT; PILOT STUDY;

ADULT; BONE DENSITY CONSERVATION AGENTS; CHI-SQUARE DISTRIBUTION; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PAIN MEASUREMENT; PILOT PROJECTS; REFLEX SYMPATHETIC DYSTROPHY; YOUNG ADULT;

EID: 58149388530     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318175920f     Document Type: Article

References (42)

1. Boas RA. Complex regional pain syndromes: symptoms, signs, and differential diagnosis. In: Stanton-Hicks M, Jänig W, eds. Reflex Sympathetic Dystrophy: A Reappraisal. Seattle: IASP Press; 1997:79-92.
2. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. 2000;16(2 suppl):S12-S20.
3. de Mos M, De Bruijn AG, Huygen FJ, et al. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007;129:12-20.
4. Sandroni P, Benrud-Larson LM, McClelland RL, et al. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain. 2003;103: 199-207.
5. Harden RN, Bruehl S, Stanos S, et al. Prospective examination of pain-related and psychological predictors of CRPS-like phenomena following total knee arthroplasty: a preliminary study. Pain. 2003;106:393-400.
6. Baron R, Binder A. Complex regional pain syndromes. In: Pappagallo M, ed. The Neurological Basis of Pain. New York: McGraw Hill; 2005.
7. Cortet B, Flipo RM, Coquerelle P, et al. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheumatol. 1997;16:51-56.
8. Cepeda MS, Carr DB, Lau J. Local anesthetic sympathetic blockade for complex regional pain syndrome [Review]. Cochrane Database Syst Rev. 2005:CD004598.
9. Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis. 1997;56:201-204.
10. Maillefert JF, Chatard C, Owen S, et al. Treatment of refractory reflex sympathetic dystrophy with pamidronate. Ann Rheum Dis. 1995;54:687.
11. Kubalek I, Fain O, Paries J, et al. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology (Oxford). 2001;40:1394-1397.
12. Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokinestimulated immunomodulators of inflammatory bone disease [Review]. Curr Opin Rheumatol. 2006;18:427-432.
13. Van Offel JF, Schuerwegh AJ, Bridts CH, et al. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol. 2001;19:13-20.
14. Varenna M, Zucchi F, Ghiringhelli D, et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol. 2000;27:1477-1483.
15. Pappagallo M, Breuer B, Schneider A, et al. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage. 2003;26:678-683.
16. Bonabello A, Galmozzi MR, Bruzzese T, et al. Analgesic effect of bisphosphonates in mice. Pain. 2001;91:269-275.
17. Fulfaro F, Casuccio A, Ticozzi C, et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain. 1998;78:157-169.
18. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol. 1999;56:131-140.
19. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. 1999;81:147-154.
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
21. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-123.
22. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
23. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope. 2006;116:115-120.
24. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:259-260.
25. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
26. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.
27. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71:111-113.
28. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg. 2004;62:391-392.
29. Robinson NA, Yeo JF. Bisphosphonates: a word of caution. Ann Acad Med Singapore. 2004;33(4 Suppl):48-49.
30. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.
31. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
32. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138.
33. Mystakidou K, Mendoza T, Tsilika E, et al. Greek brief pain inventory: validation and utility in cancer pain. Oncology. 2001;60: 35-42.
34. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332-338.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare, National Institute of Mental Health; 1976.
36. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139:101-111.
37. Santini D, Fratto ME, Vincenzi B, et al. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities [Review]. Biodrugs. 2004;18:269-278.
38. Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res. 2003;23:649-654.
39. Younes H, Farhat G, el Hajj FG. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitometry. 2002;5:143-149.
40. Berenson JR. Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials [Review]. Semin Oncol. 2001;28(2 suppl 6):25-34.
41. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9-19.
42. McQuay H. Consensus on outcome measures for chronic pain trials. Pain. 2005;113:1-2.